At what point do we start to worry about potential competition for MDVN? Could any of TKAI, EPIX, Aragon, etc. wind up with better drugs in this space?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.